Información del artículo
El Texto completo está disponible en PDF
Biblografía
[1.]
P. Beck-Peccoz, F. Brucker-Davis, L. Persani, R.C. Smallridge, B.D. Weintraub.
Thyrotropin-secreting pituitary tumors.
Endocr Rev, 17 (1996), pp. 610-638
[2.]
M. Losa, M. Giovanelli, L. Persani, P. Mortini, G. Faglia, P. Beck-Peccoz.
Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas.
J Clin Endocrinol Metab, 81 (1996), pp. 3084-3090
[3.]
P. Chanson, B.D. Weintraub, A.G. Harris.
Treatment of TSH-secreting pituitary adenomas with octreotide: a follow-up of 52 patients.
Ann Intern Med, 119 (1993), pp. 236-240
[4.]
P. Beck-Peccoz, S. Mariotti, P.J. Guillausseau.
Treatment of thyrotropin with the somatostatin analog SMS 201–295.
J Clin Endocrinol Metab, 68 (1989), pp. 208-214
[5.]
A. Gancel, P. Vuillermet, A. Legrand, F. Catus, F. Thomas, J.M. Kuhn.
Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas.
Clin Endocrinol (Oxf), 40 (1994), pp. 421-428
[6.]
L. Gourgiotis, M.C. Skarulis, F. Brucker-Davis, E.H. Oldfield, N.J. Sarlis.
Effectiviness of long-acting octeotride in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: report of two cases.
Pituitary, 4 (2001), pp. 135-143
[7.]
J.M. Kuhn, S. Arlot, H. Lefebvre, P. Caron, C. Cortet-Rudelli, F. Archambaud, et al.
Evaluation of the treatment of thyrotropinsecreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide.
J Clin Endocrinol Metab, 85 (2000), pp. 1487-1492
[8.]
A. Warnet, E. Lajeunie, F. Gelbert, M. Duet, P. Chanson, C. Cophignon, et al.
Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201–995).
Acta Endocrinol (Copenh), 124 (1991), pp. 487-491
Copyright © 2004. Sociedad Española de Endocrinología y Nutrición